The raised price target from $34 to $45 by a reputable analyst at Morgan Stanley is likely to have a positive short-term impact on Kymera Therapeutics' stock price. The Equal-Weight rating suggests a neutral stance, but the significant increase in the price target indicates improved expectations for the company's performance.